No Detail Found!

Interferon alpha - 2 b monotherapy and in combination with ribavirin as initial treatment for chronic hepatitis c

Author(s)
Javed Iqbal Farooqi Department of Medicine and Gastroenterology, Saidu Medical College, Swat, Pakistan
Rukhsana Javed Farooqi Department of Medicine, Khyber Teaching Hospital, Peshawar, Pakistan
Khalid Hameed Department of Gastroenterology, Hayatabad Medical Complex, Peshawar.Pakistan
Abstract
To compare the efficacy of interferon a-2B alone with interferon a-2B plus ribavirin combination as initial treatment for chronic hepatitis C interventional study patients. Design: Interventional study. Place and Duration of Study: The study included 183 patients who were treated for chronic hepatitis C, from January 1996 to December 1999 in Gastroenterology Dept, PGMI, Peshawar. Material and Methods: Records of interventional study patients with chronic HCV hepatitis, who were given interferon Alfa monotherapy or in combination with oral ribavirin were analyzed for baseline parameters, response rates, and any adverse effects. Results: Complete response was found in 35.29% patients in interferon monotherapy group as compared to 87.83% patients in combination group (P < 0.05). Sustained response was found in 30.88% patients in interferon monotherapy group as compared to 82.61 % patients in combination group (P < 0.05). Conclusion: Interferon plus ribavirin combination therapy is superior to interferon monotherapy in the treatment of chronic hepatitis C interventional study patients (P < 0.05)
Publication Details
Page(s) 82-85
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 12, Issue: 2, Year: 2002

Request the full text from PASTIC

Keywords
hepatitis C, Ribavirin, Hepatitis, Interferon Alfa-2B, Chronic Active
References
Tine F .1991 .Interferofnor non-A, non-B chronichepatitisa: meta-analysiosf randomizedclinicatlrialsJ. Hepatol, 13 : 192-9.
.1996 .Meta-analysiosf interferornandomizedtrialisn thetreatmenotf viral hepatitisC: effectsof dose and durationH. epatology, 24 : 778-9.
.1995 .A comparisoonf threeinterferoanlfa-2bregimensforthelong-term treatmeonftchronincon-A,non-BhepatitisN. Eng!JMed, 334 : 1143-57.
Lin R .1994 .. Gastroenterology, 107 : 812-7.
.1995 .PontissPo, AlberAti. The effectof interferoanlfaand ribavirincombinatiotnherapiyn nativepatientswith chronichepatitiCs. JHepatol, 23 : 8-12.
Yun ZB .1995 .Combined treatmenwtith interferoanlfa-2band ribavirinforchronichepatitiCs in patientwsitha previous non-responsoer non-sustainerdesponseto interferoanloneJ. Med Virol, 46 : 43-7.
. .-2bwithand without ribavirinforchronichepatitiCs. LancetV&tfy, 351 : 83-7.
Lee SS . .. , : .
.1996 .-2bplusplacebofor 48 weeks for treatmenotfchronichepatitiCs by graduarleduction treatmenotf chroni cinfectionwith hepatitisC. Lancet in theinterferodnose. Hepatology, 352 : 1426-32.
.1997 .Therapyof chronichepatitisC: overview. meta-analysiosf interferoanlfa-2btrialsH.epatology Hepatology, 26 : 83S-8S.
.1990 .. evInfectDis, 12 : 1332-46.
Cole E,productioonf TNF .1995 .IL-1, theprocoagulafngt12 prothrombinasaend preserveTsh 1 cytokineproduction butinhibitsTh 2 cytokineresponseJ. JCollPhysicians Surg Pakistan, 5 : 32-4.
.1998 .2baloneorin combination withribavirinforthetreatmenotf relapsoef chronic hepatitiCs. NEng!JMed, 339 : 1493-9.
.1995 .. profileand treatmenJtColl Physicians Surg Pakistan, 5 : 47-9.
Davis GL .1994 .nic mentof chronichepatitiCs. JHepatol, 21 : 11-3.
FleissJL .1986 .The design and analysisof clinicaelxper­i ments. NewYork.Johan WHey, : 31-47.
.1998 .. placebocontrollterdiaolf interferoan-2bwith and withoutribavirinfor chronichepatitisC. Lancet, 351 : 83-7.
Martinal-DeignoMu .1995 .Pretre­at mentserumhepatitiCs virusRNA levelsandhepatitis C virus genotypearethe main and independent prognostfiacctorosfsustainerdesponsteointerferon alfatherapiyn chronichepatitiCs. Hepatology, 22 : 1050-6.
0

Citations

0

Downloads

51

Views